Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Oncology

• Publication date

  2016-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2016.34.15_SUPPL.9568
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy

  2025cites this paper
• Checkpoint inhibitor rechallenge in advanced endometrial cancer: revisiting the immune landscape beyond first-line therapy.

  2025cites this paper
• Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors

  2025cites this paper
• Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics

  2024cites this paper
• Immunotherapy in Melanoma: Recent Advances and Future Directions

  2023cites this paper
• Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

  2023cites this paper
• Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma

  2022cites this paper
• Type I interferon-mediated tumor immunity and its role in immunotherapy

  2022cites this paper
• Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients

  2022cites this paper
• Injectables in Head and Neck Cutaneous Melanoma Treatment.

  2021cites this paper
• Systemic Therapy of Metastatic Melanoma: On the Road to Cure

  2021cites this paper
• Adjuvant immunotherapy for melanoma

  2021cites this paper
• Combinatorial Approaches to the Treatment of Advanced Melanoma.

  2021cites this paper
• Talimogene Laherparepvec in Non-Melanoma Cancers.

  2021cites this paper
• Update on Gene Therapy as an Antineoplastic Alternative

  2021cites this paper
• Next-Generation Immunotherapy Approaches in Melanoma

  2021cites this paper
• Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.

  2021cites this paper
• Perspectives of Immunotherapy in Advanced Melanoma: Combinations and Sequencing

  2021cites this paper
• Local and regional therapy for primary and locally recurrent melanoma.

  2021cites this paper
• Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.

  2020cites this paper
• Neurological Toxicities of Immunotherapy

  2020cites this paper
• Endocrine Toxicities of Immunotherapy

  2020cites this paper
• Challenges and Opportunities for Effective Cancer Immunotherapies

  2020cites this paper
• The Immune System and Pathogenesis of Melanoma and Non-melanoma Skin Cancer.

  2020cites this paper
• Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia

  2020cites this paper
• Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives

  2020cites this paper
• Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors

  2020cites this paper
• The Recent Advances of Anti-PD-1/PD-L1 Immunotherapy

  2020cites this paper
• Local and Recurrent Regional Metastases of Melanoma

  2020cites this paper
• Injectable Therapies for Regional Melanoma.

  2020cites this paper
• Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma

  2020cites this paper
• Oncolytic Viruses for the Treatment of Metastatic Melanoma

  2020cites this paper
• Melanoma immunotherapy: strategies to overcome pharmacological resistance

  2020cites this paper
• Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma

  2020cites this paper
• An evaluation of talimogene laherparepvec for the treatment of melanoma

  2020cites this paper
• Current and emerging systemic therapies for cutaneous metastatic melanoma

  2019cites this paper
• The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.

  2019cites this paper
• Immunotherapies and Novel Combinations

  2019cites this paper
• Long–Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis

  2019cites this paper
• Beyond PD-1 Immunotherapy in Malignant Melanoma

  2019cites this paper
• Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab

  2019cites this paper
• Current Immunotherapy Practices in Melanoma.

  2019cites this paper
• Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?

  2019cites this paper
• Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

  2019cites this paper
• Optimizing oncolytic virotherapy in cancer treatment

  2019cites this paper
• Novel Immunotherapies and Novel Combinations of Immunotherapy

  2019cites this paper
• Local and Recurrent Regional Metastases of Melanoma

  2019cites this paper
• Biohybrid Cloaked Nanovaccines For Cancer Immunotherapy

  2019cites this paper
• Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options

  2019cites this paper
• Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer

  2019cites this paper
• Complete clinical response to intralesional talimogene laherparepvec injection in a patient with recurrent, regionally advanced Merkel cell carcinoma

  2019cites this paper
• Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade

  2019cites this paper
• Novel Immunotherapy Combinations

  2019cites this paper
• Novel Targets for the Treatment of Melanoma

  2019cites this paper
• Evolution and effectiveness of oncolytic virotherapy as a cancer treatment

  2019cites this paper
• Regional Gene Therapy for Cancer

  2019cites this paper
• Ongoing Clinical Trials and Rationale in Regional and Oligometastatic Disease

  2019cites this paper
• Intralesional Therapies: Oncolytic Viral Therapies, Immunostimulants

  2019cites this paper
• Immune Checkpoints

  2019cites this paper
• Management of Locally and Regionally Recurrent Melanoma

  2018cites this paper
• Immune Checkpoint Inhibitors in Melanoma: Review and Update

  2018cites this paper
• A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

  2018cites this paper
• Management of local or regional non‐nodal disease

  2018cites this paper
• Dermatology today and tomorrow: from symptom control to targeted therapy

  2018cites this paper
• Intralesional therapy as a treatment for locoregionally metastatic melanoma

  2018cites this paper
• Mechanisms of Tumor Cell–Intrinsic Immune Evasion

  2018cites this paper
• Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition

  2018cites this paper
• Oncolytic Viruses: T-VEC and Others

  2018cites this paper
• Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection

  2018cites this paper
• Malignant Melanoma: Diagnostic and Management Update

  2018cites this paper
• The Role of Oncolytic Viruses in the Treatment of Melanoma

  2018cites this paper
• Oncolytic virus immunotherapy: future prospects for oncology

  2018cites this paper
• Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?

  2018cites this paper
• Regional therapies for locoregionally advanced and unresectable melanoma

  2018cites this paper
• Challenging the standard of care in advanced melanoma: focus on pembrolizumab

  2017cites this paper
• Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

  2017cites this paper
• Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016

  2017cites this paper
• Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors

  2017influential citation
• Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma

  2017influential citation
• Intratumoral Approaches for the Treatment of Melanoma

  2017cites this paper
• Treatment of advanced melanoma - A changing landscape.

  2017cites this paper
• Review: Oncolytic Virotherapy, updates and future directions.

  2017cites this paper
• Sarcoma Development of Checkpoint Inhibitors for Sarcomas

  2017cites this paper
• A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma

  2017cites this paper
• [Malignant melanoma : Current status].

  2017cites this paper
• Pattern recognition receptors: immune targets to enhance cancer immunotherapy

  2017cites this paper
• Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer

  2017cites this paper
• PD-1 and PD-L1 antibodies in cancer: current status and future directions

  2017cites this paper
• Intralesional treatment of metastatic melanoma: a review of therapeutic options

  2017cites this paper
• Resistance to PD1/PDL1 checkpoint inhibition.

  2017cites this paper
• Combination immunotherapy: a road map The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

  2017cites this paper
• Immunotherapy in managing metastatic melanoma: which treatment when?

  2017cites this paper
• The benefits of immunotherapy combinations

  2017cites this paper
• Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

  2017cites this paper
• Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases

  2017cites this paper
• New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone

  2017cites this paper
• Oncolytic Virotherapy: A Contest between Apples and Oranges.

  2017cites this paper
• Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab

  2017cites this paper
• Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies

  2017cites this paper
• Advances in clinical immunotherapy of melanoma

  2017cites this paper